Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. The Company’s multi antigen recognizing (MAR)-T cell technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens, which are tumor targets, and kill tumor cells expressing those targets. These T cells are designed to recognize multiple tumor targets to produce broad-spectrum anti-tumor activity. It is developing two product candidates, including an Autologous MAR-T cell product for the treatment of lymphoma and pancreatic cancer (MT-601) and an Off-the-Shelf (OTS) product in various indications (MT-401-OTS). It has developed MT-601 to recognize multiple target antigens expressed by the tumor, thereby limiting tumor adaptation by negative antigen selection or downregulation.
Símbolo de cotizaciónMRKR
Nombre de la empresaMarker Therapeutics Inc
Fecha de salida a bolsaNov 08, 2016
Fundada en2018
Director ejecutivoDr. Juan F. Vera, M.D.
Número de empleados5
Tipo de seguridadOrdinary Share
Fin del año fiscalNov 08
Dirección2450 Holcombe Blvd
CiudadHOUSTON
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal77021
Teléfono17134006400
Sitio Webhttps://markertherapeutics.com/
Símbolo de cotizaciónMRKR
Fecha de salida a bolsaNov 08, 2016
Fundada en2018
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.

Sin datos